MCID: VSC018
MIFTS: 37

Visceral Steatosis malady

Categories: Rare diseases, Liver diseases

Aliases & Classifications for Visceral Steatosis

Aliases & Descriptions for Visceral Steatosis:

Name: Visceral Steatosis 50 52
Fatty Metamorphosis of Viscera 50 69
Fatal Neonatal Hepatic Steatosis 50
White Liver Disease 50
Steatosis of Liver 50
Steatohepatitis 69

Characteristics:

HPO:

32
visceral steatosis:
Mortality/Aging neonatal death
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Visceral Steatosis

MalaCards based summary : Visceral Steatosis, also known as fatty metamorphosis of viscera, is related to fatty liver disease and hyperammonemia, and has symptoms including abnormality of the genitourinary system, renal steatosis and jaundice. An important gene associated with Visceral Steatosis is SLC22A5 (Solute Carrier Family 22 Member 5), and among its related pathways/superpathways are AMP-activated Protein Kinase (AMPK) Signaling and AMPK Enzyme Complex Pathway. The drugs Rosiglitazone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and hypothalamus.

Related Diseases for Visceral Steatosis

Diseases related to Visceral Steatosis via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 fatty liver disease 11.0
2 hyperammonemia 9.9
3 van maldergem syndrome 9.8 CPT1A CPT1B
4 deafness, congenital with inner ear agenesis, microtia, and microdontia 9.8 CPT1A CPT1B
5 encephalopathy, acute, infection-induced, 4 9.7 CPT1A CPT1B
6 azoospermia 9.7
7 wagner syndrome 9.6 CPT1A CPT1B SLC22A5

Graphical network of the top 20 diseases related to Visceral Steatosis:



Diseases related to Visceral Steatosis

Symptoms & Phenotypes for Visceral Steatosis

Human phenotypes related to Visceral Steatosis:

32 (show all 13)
id Description HPO Frequency HPO Source Accession
1 abnormality of the genitourinary system 32 HP:0000119
2 renal steatosis 32 HP:0000799
3 jaundice 32 HP:0000952
4 seizures 32 HP:0001250
5 muscular hypotonia 32 HP:0001252
6 lethargy 32 HP:0001254
7 coma 32 HP:0001259
8 kernicterus 32 HP:0001343
9 hepatic steatosis 32 HP:0001397
10 abnormal bleeding 32 HP:0001892
11 hypoglycemia 32 HP:0001943
12 hypocalcemia 32 HP:0002901
13 myocardial steatosis 32 HP:0006693

Drugs & Therapeutics for Visceral Steatosis

Drugs for Visceral Steatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 404)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 4,Phase 2 122320-73-4 77999
2
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
3
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
6
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
7
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
8
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
9
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
10
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
11
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
14
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
15
Cortisone acetate Approved Phase 4 1950-04-4, 50-04-4 5745
16
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
17
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
18
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
19
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
20
Tamoxifen Approved Phase 4 10540-29-1 2733526
21
Gliclazide Approved Phase 4 21187-98-4 3475
22
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
23
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
24
Selenium Approved, Vet_approved Phase 4 7782-49-2
25
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
26
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
27
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2
28
Menthol Approved Phase 4 2216-51-5 16666
29
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
30
Insulin Aspart Approved Phase 4 116094-23-6 16132418
31
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
32
Insulin Detemir Approved Phase 4 169148-63-4 5311023
33
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
34
Rifampin Approved Phase 4 13292-46-1 5458213 5381226
35
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
36
Glimepiride Approved Phase 4 93479-97-1 3476
37
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
38
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
39
Saxagliptin Approved Phase 4 361442-04-8 11243969
40
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
41
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
42
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
43
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
44
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-02-9 14985
45
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 65-23-6 1054
46
Choline Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1 62-49-7 305
47
Riboflavin Approved, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
48
Thiamine Approved, Nutraceutical, Vet_approved Phase 4 59-43-8 1130
49
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3,Phase 2 66-72-8 1050
50
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795

Interventional clinical trials:

(show top 50) (show all 743)
id Name Status NCT ID Phase
1 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
2 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4
3 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4
4 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
5 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4
6 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4
7 Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity Unknown status NCT00878592 Phase 4
8 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
9 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Unknown status NCT02277587 Phase 4
10 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4
11 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4
12 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4
13 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4
14 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4
15 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4
16 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4
17 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4
18 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4
19 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4
20 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4
21 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4
22 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4
23 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4
24 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4
25 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4
26 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4
27 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
28 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4
29 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4
30 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
31 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4
32 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4
33 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4
34 Complex Imaging Assessment of Steatosis Recruiting NCT02669641 Phase 4
35 Fatty Liver Study in Patients With Type II Diabetes Recruiting NCT02365233 Phase 4
36 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Recruiting NCT01720719 Phase 4
37 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Recruiting NCT02147925 Phase 4
38 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Recruiting NCT02213224 Phase 4
39 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Recruiting NCT02721888 Phase 4
40 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4
41 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Recruiting NCT02051842 Phase 4
42 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Recruiting NCT02875821 Phase 4
43 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4
44 Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. Recruiting NCT03007329 Phase 4
45 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4
46 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4
47 The Effects of PXR Activation on Hepatic Fat Content Recruiting NCT02329405 Phase 4
48 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Recruiting NCT02637973 Phase 4
49 SMOFLipid in Intralipid Intolerant Recruiting NCT03054948 Phase 4
50 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Recruiting NCT02733679 Phase 4

Search NIH Clinical Center for Visceral Steatosis

Genetic Tests for Visceral Steatosis

Anatomical Context for Visceral Steatosis

MalaCards organs/tissues related to Visceral Steatosis:

39
Liver, Heart, Hypothalamus

Publications for Visceral Steatosis

Articles related to Visceral Steatosis:

(show all 33)
id Title Authors Year
1
Failure of the feeding response to fasting in carnitine-deficient juvenile visceral steatosis (JVS) mice: involvement of defective acyl-ghrelin secretion and enhanced corticotropin-releasing factor signaling in the hypothalamus. ( 19744557 )
2009
2
Expression and distribution of OCTN2 in mouse epididymis and its association with obstructive azoospermia in juvenile visceral steatosis mice. ( 16734862 )
2006
3
Attenuation of cardiac hypertrophy in carnitine-deficient juvenile visceral steatosis (JVS) mice achieved by lowering dietary lipid. ( 16452314 )
2006
4
Identification of the up- and down-regulated genes in the heart of juvenile visceral steatosis mice. ( 15056854 )
2004
5
Functional disorders of the oxidative phosphorylation system in the heart mitochondria of mice with juvenile visceral steatosis. ( 12612434 )
2003
6
Effect of gamma-butyrobetaine on fatty liver in juvenile visceral steatosis mice. ( 11341370 )
2001
7
Antagonizing effect of AP-1 on glucocorticoid induction of urea cycle enzymes: a study of hyperammonemia in carnitine-deficient, juvenile visceral steatosis mice. ( 11136545 )
2000
8
The signaling pathway of cardiotrophin-1 is not activated in hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 10904873 )
2000
9
Cardiomegaly in the juvenile visceral steatosis (JVS) mouse is reduced with acute elevation of heart short-chain acyl-carnitine level after L-carnitine injection. ( 10025944 )
1999
10
Catecholamine metabolism inhibitors and receptor blockades only partially suppress cardiac hypertrophy of juvenile visceral steatosis mice with systemic carnitine deficiency. ( 10210276 )
1999
11
Dysfunctions of the epididymis as a result of primary carnitine deficiency in juvenile visceral steatosis mice. ( 10100867 )
1999
12
Pyruvate dehydrogenase kinase 4 mRNA is increased in the hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 10609898 )
1999
13
Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ( 10087008 )
1999
14
Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. ( 10498652 )
1999
15
Characteristics of cardiac hypertrophy in the juvenile visceral steatosis mouse with systemic carnitine deficiency. ( 9602426 )
1998
16
A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. ( 9837751 )
1998
17
Abnormal gene expression causing hyperammonemia in carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 9286432 )
1997
18
Secondary abnormality of carnitine biosynthesis results from carnitine reabsorptional system defect in juvenile visceral steatosis mice. ( 9540857 )
1997
19
A novel gene suppressed in the ventricle of carnitine-deficient juvenile visceral steatosis mice. ( 9187371 )
1997
20
Suppressed expression of the urea cycle enzyme genes in the liver of carnitine-deficient juvenile visceral steatosis (JVS) mice in infancy and during starvation in adulthood. ( 9058209 )
1997
21
The effect of carnitine on ketogenesis in perfused livers from juvenile visceral steatosis mice with systemic carnitine deficiency. ( 9212045 )
1997
22
Increased expression of carnitine palmitoyltransferase I gene is repressed by administering L-carnitine in the hearts of carnitine-deficient juvenile visceral steatosis mice. ( 8830050 )
1996
23
Altered expression of carnitine palmitoyltransferase II in liver, muscle, and heart of mouse strain with juvenile visceral steatosis. ( 8605222 )
1996
24
Disordered expression of glycolytic and gluconeogenic liver enzymes of juvenile visceral steatosis mice with systemic carnitine deficiency. ( 8858199 )
1996
25
Carnitine transport defect in fibroblasts of juvenile visceral steatosis (JVS) mouse. ( 8670273 )
1996
26
Mitochondrial abnormalities of muscle tissue in mice with juvenile visceral steatosis associated with systemic carnitine deficiency. ( 7773507 )
1995
27
Mapping of jvs (juvenile visceral steatosis) gene, which causes systemic carnitine deficiency in mice, on chromosome 11. ( 7626891 )
1995
28
Primary defect of juvenile visceral steatosis (jvs) mouse with systemic carnitine deficiency is probably in renal carnitine transport system. ( 8155735 )
1994
29
Cardiac hypertrophy in juvenile visceral steatosis (jvs) mice with systemic carnitine deficiency. ( 8325377 )
1993
30
Carnitine administration to juvenile visceral steatosis mice corrects the suppressed expression of urea cycle enzymes by normalizing their transcription. ( 1544887 )
1992
31
Abnormal expression of urea cycle enzyme genes in juvenile visceral steatosis (jvs) mice. ( 1540663 )
1992
32
Proto-oncogene c-jun and c-fos messenger RNAs increase in the liver of carnitine-deficient juvenile visceral steatosis (jvs) mice. ( 1383034 )
1992
33
Animal model of systemic carnitine deficiency: analysis in C3H-H-2 degrees strain of mouse associated with juvenile visceral steatosis. ( 1996978 )
1991

Variations for Visceral Steatosis

Expression for Visceral Steatosis

Search GEO for disease gene expression data for Visceral Steatosis.

Pathways for Visceral Steatosis

GO Terms for Visceral Steatosis

Cellular components related to Visceral Steatosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial outer membrane GO:0005741 8.62 CPT1A CPT1B

Biological processes related to Visceral Steatosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transport GO:0006810 9.5 CPT1A CPT1B SLC22A5
2 fatty acid metabolic process GO:0006631 9.26 CPT1A CPT1B
3 fatty acid beta-oxidation GO:0006635 9.16 CPT1A CPT1B
4 carnitine shuttle GO:0006853 8.96 CPT1A CPT1B
5 carnitine metabolic process GO:0009437 8.62 CPT1A SLC22A5

Molecular functions related to Visceral Steatosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transferase activity, transferring acyl groups GO:0016746 8.96 CPT1A CPT1B
2 carnitine O-palmitoyltransferase activity GO:0004095 8.62 CPT1A CPT1B

Sources for Visceral Steatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....